New Two-Step transplant shows promise for tough blood cancers

NCT ID NCT03032783

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 2 trial tested a two-step donor stem cell transplant in 51 people with high-risk blood cancers. The approach uses total-body irradiation and chemotherapy to prepare the body, then infuses donor stem cells and later donor immune cells. The goal is to boost the anti-cancer effect while limiting severe side effects. The study looked at overall survival at two years and rates of graft failure and early death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
donor stem cells (with total-body irradiation, donor lymphocyte infusion, and cyclophosphamide)
What this could lead to
If successful, this approach could offer a safer way to perform donor stem cell transplants for people with high-risk blood cancers, potentially improving survival rates.
What could go wrong
This is a completed phase 2 trial with only 51 participants, so results are preliminary. The treatment carries risks like graft failure, severe infection, and organ damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOPOIETIC AND LYMPHOID CELL NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

    Philadephia, Pennsylvania, 19107, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.